PL4025612T3 - Przeciwciała anty-fukozylo-gm1 - Google Patents

Przeciwciała anty-fukozylo-gm1

Info

Publication number
PL4025612T3
PL4025612T3 PL20767753.5T PL20767753T PL4025612T3 PL 4025612 T3 PL4025612 T3 PL 4025612T3 PL 20767753 T PL20767753 T PL 20767753T PL 4025612 T3 PL4025612 T3 PL 4025612T3
Authority
PL
Poland
Prior art keywords
fucosyl
antibodies
Prior art date
Application number
PL20767753.5T
Other languages
English (en)
Inventor
Linda Gillian Durrant
Original Assignee
Scancell Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scancell Limited filed Critical Scancell Limited
Publication of PL4025612T3 publication Critical patent/PL4025612T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL20767753.5T 2019-09-03 2020-09-02 Przeciwciała anty-fukozylo-gm1 PL4025612T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1912657.2A GB201912657D0 (en) 2019-09-03 2019-09-03 Binding members
PCT/EP2020/074441 WO2021043810A1 (en) 2019-09-03 2020-09-02 Anti-fucosyl-gm1 antibodies

Publications (1)

Publication Number Publication Date
PL4025612T3 true PL4025612T3 (pl) 2026-04-27

Family

ID=68207228

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20767753.5T PL4025612T3 (pl) 2019-09-03 2020-09-02 Przeciwciała anty-fukozylo-gm1

Country Status (15)

Country Link
US (1) US12552876B2 (pl)
EP (1) EP4025612B1 (pl)
JP (1) JP7672395B2 (pl)
KR (1) KR20220054648A (pl)
CN (1) CN114729057B (pl)
AU (1) AU2020340691A1 (pl)
BR (1) BR112022003568A2 (pl)
CA (1) CA3150555A1 (pl)
DK (1) DK4025612T3 (pl)
ES (1) ES3060303T3 (pl)
FI (1) FI4025612T3 (pl)
GB (1) GB201912657D0 (pl)
PL (1) PL4025612T3 (pl)
PT (1) PT4025612T (pl)
WO (1) WO2021043810A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE121C (de) 1877-08-10 FISCHER & STIEHL in Essen Verfahren zur Kühlung und Vorwärmung der Luft mit Hülfe der Erdwärme
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS5811808A (ja) 1981-07-16 1983-01-22 Niles Parts Co Ltd 方位検出表示回路
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0142541B1 (en) 1983-05-09 1987-07-08 THE GENERAL ELECTRIC COMPANY, p.l.c. Cathode ray tube display device
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
WO1999015201A1 (en) * 1997-09-25 1999-04-01 Sloan-Kettering Institute For Cancer Research Fucosyl gm1-klh conjugate vaccine against small cell lung cancer
US7854934B2 (en) 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
EP1960434B1 (en) 2005-12-08 2012-07-11 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
US20170247466A1 (en) 2014-09-25 2017-08-31 Bristol-Myers Squibb Company Treatment of lung cancer using an anti-fucosyl-gm1 antibody
JP2024503379A (ja) * 2021-01-08 2024-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗フコシルｇｍ１抗体を使用した組み合わせ療法

Also Published As

Publication number Publication date
JP7672395B2 (ja) 2025-05-07
JP2022546762A (ja) 2022-11-08
CN114729057B (zh) 2024-09-03
FI4025612T3 (fi) 2026-01-30
GB201912657D0 (en) 2019-10-16
DK4025612T3 (da) 2026-02-02
US12552876B2 (en) 2026-02-17
WO2021043810A1 (en) 2021-03-11
BR112022003568A2 (pt) 2022-05-24
PT4025612T (pt) 2025-12-30
CA3150555A1 (en) 2021-03-11
WO2021043810A8 (en) 2025-07-03
AU2020340691A1 (en) 2022-03-24
EP4025612A1 (en) 2022-07-13
ES3060303T3 (en) 2026-03-25
EP4025612B1 (en) 2025-10-29
KR20220054648A (ko) 2022-05-03
CN114729057A (zh) 2022-07-08
US20220267466A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
IL280780A (en) Anti-TIGIT antibodies
IL291068A (en) Anti-cd73 antibodies
IL289112A (en) Antibodies against tigit
IL280013A (en) Anti-IL36R antibodies
SG11202108141VA (en) Novel cd40-binding antibodies
IL279352A (en) IL-11RA antibodies
GB201905150D0 (en) Ant-ige antibodies
IL278010A (en) Antibodies to galectin 10
IL277030A (en) Antibodies
SG11202106171WA (en) Anti-btla antibodies
IL284584A (en) Anti-tigit antibodies
ZA202108836B (en) Anti-epha4 antibody
GB2581174B (en) Antibodies against hEPCR
GB201811368D0 (en) Antibody
SG11202102114UA (en) Anti-klrg1 antibodies
IL300142A (en) Anti-IL13Ralpha2 antibodies
GB201900732D0 (en) Antibodies
GB201806084D0 (en) Antibodies
GB201917480D0 (en) Antibodies
GB201919062D0 (en) Antibody
SG11201913540VA (en) Anti-Podoplanin Antibody
IL289160A (en) Anti-angpt2 antibodies
PT4025612T (pt) Anticorpos anti-fucosil-gm1
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
GB201919280D0 (en) Antibodies